Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BL-M07D1 vs T-DM1 in adjuvant treatment of HER2-positive breast cancer with residual invasive disease after neoadjuvant therapy
CTR20250479Phase 3Active
- Sponsor
- Biokin Pharmaceutical
- Start
- Jun 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of BL-M07D1 in breast cancer, sponsored by Biokin Pharmaceutical. Started Jun 2025; status: active.
02
Drugs
BL-M07D1
03
Conditions
breast cancer
Beyond the preview
Go deeper on CTR20250479.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20250479.